单核细胞计数与突发CKD及进展至ESRD风险之间的关联
在1,594,700名美国退伍军人中构建纵向观察队列,中位随访9.2年,按单核细胞计数四分位分组。调整生存模型显示,第四组较第一组突发eGFR<60、突发CKD、血清肌酐翻倍、eGFR下降≥30%及复合肾脏终点的风险均升高,呈线性关系,敏感性分析结果稳健。
要点
- 单核细胞计数最高四分位组与突发CKD风险升高相关(HR 1.15,95%CI 1.13-1.16)。
- 最高四分位组与CKD进展风险升高相关,包括血清肌酐翻倍(HR 1.22)和eGFR下降≥30%(HR 1.18)。
- 单核细胞计数与肾脏结局风险呈线性关系,计数越高风险越高。
核心结论
- 研究结果显示,较高的单核细胞计数与突发CKD及CKD进展至ESRD的风险存在显著关联。
研究设计与样本
- 研究为纵向观察队列,纳入1,594,700名美国退伍军人,要求2004财年至少有一次eGFR且无ESRD、透析或肾移植史,随访至2013年9月30日或死亡。
- 单核细胞计数按最接近且早于时间零点的数值分为四分位:第一组>0.00至≤0.40千个/立方毫米,第二组>0.40至≤0.55千个/立方毫米,第三组>0.55至≤0.70千个/立方毫米,第四组>0.70千个/立方毫米。
主要发现
- 中位随访9.2年(四分位距8.3-9.4年),调整生存模型显示单核细胞计数与肾脏结局风险呈分级关联。
- 与第一组相比,第四组突发eGFR<60毫升/分钟/1.73平方米的风险升高(HR 1.13,95%CI 1.12至1.14),突发CKD风险升高(HR 1.15,95%CI 1.13至1.16)。
- 第四组血清肌酐翻倍风险升高(HR 1.22,95%CI 1.20至1.24),eGFR下降≥30%风险升高(HR 1.18,95%CI 1.17至1.19),复合肾脏终点风险升高(HR 1.19,95%CI 1.16至1.22)。
- 立方样条分析显示单核细胞计数水平与肾脏结局之间呈线性关系,计数越高风险越高,敏感性分析结果稳健。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Experimental evidence suggests a role for monocytes in the biology of kidney disease progression; however, whether monocyte count is associated with risk of incident CKD, CKD progression, and ESRD has not been examined in large epidemiologic studies. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: We built a longitudinal observational cohort of 1,594,700 United States veterans with at least one eGFR during fiscal year 2004 (date of last eGFR during this period designated time zero) and no prior history of ESRD, dialysis, or kidney transplant. Cohort participants were followed until September 30, 2013 or death. Monocyte count closest to and before time zero was categorized in quartiles: quartile 1, >0.00 to ≤0.40 thousand cells per cubic millimeter (k/cmm); quartile 2, >0.40 to ≤0.55 k/cmm; quartile 3, >0.55 to ≤0.70 k/cmm; and quartile 4, >0.70 k/cmm. Survival models were built to examine the association between monocyte count and risk of incident eGFR<60 ml/min per 1.73 m2, risk of incident CKD, and risk of CKD progression defined as doubling of serum creatinine, eGFR decline ≥30%, or the composite outcome of ESRD, dialysis, or renal transplantation. RESULTS: Over a median follow-up of 9.2 years (interquartile range, 8.3-9.4); in adjusted survival models, there was a graded association between monocyte counts and risk of renal outcomes. Compared with quartile 1, quartile 4 was associated with higher risk of incident eGFR<60 ml/min per 1.73 m2 (hazard ratio, 1.13; 95% confidence interval, 1.12 to 1.14) and risk of incident CKD (hazard ratio, 1.15; 95% confidence interval, 1.13 to 1.16). Quartile 4 was associated with higher risk of doubling of serum creatinine (hazard ratio, 1.22; 95% confidence interval, 1.20 to 1.24), ≥30% eGFR decline (hazard ratio, 1.18; 95% confidence interval, 1.17 to 1.19), and the composite renal end point (hazard ratio, 1.19; 95% confidence interval, 1.16 to 1.22). Cubic spline analyses of the relationship between monocyte count levels and renal outcomes showed a linear relationship, in which risk was higher with higher monocyte count. Results were robust to changes in sensitivity analyses. CONCLUSIONS: Our results show a significant association between higher monocyte count and risks of incident CKD and CKD progression to ESRD.
引用
- Bowe B, Xie Y, Xian H, et al. Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD. Clin J Am Soc Nephrol. 2017. PMID: 28348030. doi:10.2215/CJN.09710916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。